株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Symphogen A/Sの製品パイプライン分析

Symphogen A/S - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 192838
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
Symphogen A/Sの製品パイプライン分析 Symphogen A/S - Product Pipeline Review - 2016
出版日: 2016年12月21日 ページ情報: 英文 38 Pages
概要

Symphogen A/Sはデンマークに本社を持つバイオ製薬企業であり、癌、感染症、自己免疫疾患の次世代抗体治療薬開発に利用される遺伝子組換え抗体混合物を開発しています。

当レポートでは、Symphogen A/Sにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Symphogen A/Sの基本情報

  • Symphogen A/Sの概要
  • 主要情報
  • 企業情報

Symphogen A/S:R&Dの概要

  • 主な治療範囲

Symphogen A/S:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Symphogen A/S:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Symphogen A/S:薬剤プロファイル

  • Sym-002
  • Sym-003
  • Sym-005
  • Sym-006
  • Sym-011
  • Sym-013
  • Monoclonal Antibodies 1 for Cancer
  • Monoclonal Antibodies for Cancer
  • Monoclonal Antibodies to Target Multiple Receptors for Cancer
  • Sym-007
  • Sym-008
  • Sym-009
  • Sym-012
  • Sym-014
  • SYM-015

Symphogen A/S:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Symphogen A/S:最新のパイプライン情報

Symphogen A/S:開発休止中のプロジェクト

Symphogen A/S:開発が中止された製品

Symphogen A/S:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

目次
Product Code: GMDHC08173CDB

Summary

Global Markets Direct's, 'Symphogen A/S - Product Pipeline Review - 2016', provides an overview of the Symphogen A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Symphogen A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Symphogen A/S
  • The report provides overview of Symphogen A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Symphogen A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Symphogen A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Symphogen A/S's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Symphogen A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Symphogen A/S's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Symphogen A/S Snapshot
    • Symphogen A/S Overview
    • Key Facts
  • Symphogen A/S - Research and Development Overview
    • Key Therapeutic Areas
  • Symphogen A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Symphogen A/S - Pipeline Products Glance
    • Symphogen A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Symphogen A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Symphogen A/S - Drug Profiles
    • futuximab + modotuximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TIM-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sym-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYM-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Symphogen A/S - Pipeline Analysis
  • Symphogen A/S - Pipeline Products by Target
  • Symphogen A/S - Pipeline Products by Route of Administration
  • Symphogen A/S - Pipeline Products by Molecule Type
  • Symphogen A/S - Pipeline Products by Mechanism of Action
  • Symphogen A/S - Dormant Projects
  • Symphogen A/S - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • rozrolimupab
  • Symphogen A/S - Company Statement
  • Symphogen A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Symphogen A/S, Key Facts
  • Symphogen A/S - Pipeline by Indication, 2016
  • Symphogen A/S - Pipeline by Stage of Development, 2016
  • Symphogen A/S - Monotherapy Products in Pipeline, 2016
  • Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016
  • Symphogen A/S - Phase II, 2016
  • Symphogen A/S - Phase I, 2016
  • Symphogen A/S - Preclinical, 2016
  • Symphogen A/S - Discovery, 2016
  • Symphogen A/S - Pipeline by Target, 2016
  • Symphogen A/S - Pipeline by Route of Administration, 2016
  • Symphogen A/S - Pipeline by Molecule Type, 2016
  • Symphogen A/S - Pipeline Products by Mechanism of Action, 2016
  • Symphogen A/S - Dormant Developmental Projects,2016
  • Symphogen A/S - Discontinued Pipeline Products, 2016
  • Symphogen A/S, Subsidiaries

List of Figures

  • Symphogen A/S - Pipeline by Top 10 Indication, 2016
  • Symphogen A/S - Pipeline by Stage of Development, 2016
  • Symphogen A/S - Monotherapy Products in Pipeline, 2016
  • Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016
  • Symphogen A/S - Pipeline by Target, 2016
  • Symphogen A/S - Pipeline by Route of Administration, 2016
  • Symphogen A/S - Pipeline by Molecule Type, 2016
  • Symphogen A/S - Pipeline Products by Mechanism of Action, 2016
Back to Top